Roche and Merck begin expanded access programs for protease inhibitor drugs.
Baker
R
R
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D018791:CD4 Lymphocyte Count; D004345:Drug Industry; D017320:HIV Protease Inhibitors / Q000600:supply & distribution / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir; D007546:Isoquinolines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D011897:Random Allocation; D019258:Saquinavir
D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011725:Pyridines; D011804:Quinolines; D019469:Indinavir; D019258:Saquinavir